Secondary outcomes included the operative time (skin to skin), postoperative complications, duration of hospital stay, rate of conversion to the open technique, improvements in the quality of life, amelioration of obesity-related comorbidities, and change in the level of GLP-1 6 weeks postoperative. The gene discussed is GCG; the disease is obesity disorder.